Cannabis Law Report

JUNE 16, 2022

million cultivated marijuana plants and made more than 6,600 marijuana-related arrests in 2021, according to annual data compiled by the US Drug Enforcement Administration. . Federal law enforcement agents and their partners seized over 5.5 million cultivated cannabis plants last year – a 20 percent increase over 2020’s totals.

DEA 52

DEA Marijuana Programs Data 52

The Cannigma

MAY 16, 2025

So while a cannabis business can join their local chamber of commerce, a patient in hospice can be denied access to medical cannabis. The unstable legality of federal protections for medical cannabis, which solely come from an amendment to the DOJ and DEAs budget that has to pass every year, threatens our progress. Make it make sense.

Policy 79

Policy Access Advocacy Patients 79

Cannabis Law Report

JUNE 16, 2021

Social listening data reveals that conversations around Delta-8 grew by a whopping 163% from December 2020 to April 2021, but all is not rosy for this latest trend in cannabis or for companies jumping into production to respond to the surging interest. Using this metric, a full 32% of the products tested merited an “F” (Fail) accuracy rating.

THC 90

THC Hemp Media Data 90

Veriheal

JUNE 30, 2023

The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

DECEMBER 27, 2022

The subjective nature of self-reported data can plague research. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

JUNE 15, 2021

Reinvests funds to support programs that work on expanding access to substance use treatment, support harm reduction services, and reduce the criminalization of individuals who use drugs by supporting the development or expansion of pre-arrest diversion programs. Ensures individuals with drug convictions can gain access to drivers’ licenses.

Decriminalization 60

Decriminalization Policy Research and Development Data 60

Cannabis Law Report

JUNE 1, 2021

.” 1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

SEPTEMBER 23, 2021

Tracking recent data from within the last year (following the publication of the DEA Interim Final Rule which added confusion to the delta-8 legality question), more than a dozen hospital or emergency room visits and hundreds of calls to poison control were reported.

THC 52

THC Concentrates Pets DEA 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D., MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Medicinal Genomics

NOVEMBER 12, 2024

As a result, labs that have received a state license to test either medical or recreational cannabis have historically been denied a DEA Schedule I license to test hemp under the 2018 Farm Bill. However, this may change with rescheduling that is going to be revisited on Dec 2, 2024.

Compliance 52

Compliance Compliance Data Agriculture 52

Cannabis Law Report

AUGUST 6, 2021

1 Unless otherwise indicated, market share data disclosed in this press release is calculated using the Company’s internal proprietary market share tool that utilizes point of sales data supplied by a third-party data provider, government agencies and our own retail store operations across the country. Webcast Information.

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

OCTOBER 14, 2021

The study, conducted independently by Colorado State University researchers and published in the peer-reviewed, open-access scientific journal Pharmaceuticals , explored the pharmacokinetics of edible THC. This pharmacokinetic data lays the groundwork for understanding how our products work in the body.

THC 40

THC Edibles Cannabinoids Data 40

Cannabis Law Report

MAY 17, 2019

Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. A wildly popular nutritional supplement and food additive, oil based hemp derived products like CBD racked up $1.1 Farm Bill’s Impact and Rise of the FDA. Beyond removing plant cannabis sativa L. Budgeted at $6.1

Food 10

Food DEA Hemp CBD 10

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Info

MARCH 21, 2019

have legalized cannabis for either recreational or medical uses, allowing companies to thrive, the plant is still illegal on a Federal level – classified as a Schedule I drug by the DEA. Moreover, most people usually don’t have access to the resources needed to make an informed assessment of a company. While multiple states in the U.S.

Marijuana 59

Marijuana Pharmaceutical Hash Cannabinoids 59

Cannabis Law Report

APRIL 14, 2022

pursuant to Drug Enforcement Agency (DEA) or state-level programs). Before legalization, illicit grow sites did not have access to water utilities and were typically grown in arid/remote areas, often depleting local surface water and shallow aquifers not suited to intensive use. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

SpeedWeed

DECEMBER 28, 2018

Which Cannabis Strains Are Highest in CBD, According to Lab Data? Bummer: Patients Are Still Struggling for Cannabis Access. There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. RELATED STORY. RELATED STORY.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 119

Research and Development Education Agriculture Patients 119

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 23, 2021

Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). It would transfer primary agency jurisdiction over cannabis from the DEA to the FDA, TTB, and ATF. If implemented, regulatory responsibility of cannabis would be transferred from the U.S.

Research and Development 81

Research and Development DEA Programs State Laws 81

CannaMD

SEPTEMBER 15, 2020

MORE DETAILS: On June 16, 2014, Florida became the 22nd state to legalize (at least partial) access to medical marijuana when Governor Rick Scott signed the Compassionate Medical Cannabis Act of 2014. After this data has been entered, the information will be reviewed and you will receive your medical marijuana card.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Law Report

NOVEMBER 4, 2021

The President could pursue the appointment of agency officials who favor descheduling, or use executive orders to direct DEA, HHS, and FDA to consider administrative descheduling of marijuana. But I do think it makes sense, based on data, that we should study what the long-term effects are for the use of marijuana. We’re beyond that.”.

DEA 52

DEA Marijuana Decriminalization Data 52

Cannabis Law Report

NOVEMBER 2, 2021

The investigation covered a lot of important ground, but the main results concern the levels of delta-9 THC in each product, the inaccuracy of the labeling, how easily minors can get access to products and whether companies test for impurities. Every lab uses a different method so the data is not going to be consistent.”.

THC 96

THC CBD Legalization Vaping 96

SpeedWeed

JULY 22, 2021

The attorney general can also choose to waive that right and let the DEA review the petition instead. . Each day cannabis remains overly scheduled, patients and researchers across the United States continue to lose access to life-saving therapies and data.”. And Joyce and Young’s cannabis activism doesn’t end there.

DEA 52

DEA Therapy Cannabis Patients 52

SpeedWeed

AUGUST 19, 2021

In recent months, a synthetic compound derived from hemp called THC-O acetate—often referred to simply as THC-O (pronounced “THC oh”)—has quickly gained popularity among Americans who don’t have access to legal cannabis. . THC-O products are increasingly popular in states where consumers don’t have access to legal cannabis.

THC 40

THC Hemp Extraction Vaping 40

Cannabis Law Report

SEPTEMBER 19, 2019

This leaves room for further growth, which may occur from the recent legalization of smokable flower and continued wide access to dispensaries.” Namely that Florida is the second-fastest-growing market in terms of patients joining the registry, with registered patients making up 1.6% of the state’s total population.

Vaping 55

Vaping Hemp Education Patients 55

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational Data Cannabis DEA 52

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. Dr. Sue Sisley. Later that night, everyone celebrated at a hotel bar.

DEA 242

DEA Research and Development Clinical Trials Patients 242

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. That power is typically delegated to the DEA. Psilocybin’s federal status as a Schedule I controlled substance is to blame.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

NORML

FEBRUARY 18, 2020

Because cannabis is still illegal under federal law, the DEA and other federal law enforcement would be able to use federal funds to shut down medical marijuana programs. The data speaks for itself. No patient should have to worry about losing access to cannabis treatment options. Thanks for being in the fight with us, NORML.

Marijuana 361

Marijuana DEA Programs Patients 361

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. iii) except as provided in subparagraph (B), any activity that is limited to—. . (I)

Banking 45

Banking Law Marijuana State Laws 45